Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.71 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.71 |
| ▸ | IDO1 | P14902 | 2/20 | 0.57 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6774918 | 0.86 | CYP11B1 (0.82) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL6928571 | 0.84 | CYP11B1 (0.56) | CYP11B1CYP11B2 | |
| SCHEMBL6599640 | 0.84 | CYP11B1 (0.72) | CYP11B1CYP11B2HTT | |
| SCHEMBL2104118 | 0.84 | CYP11B1 (0.64) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL6599807 | 0.83 | CYP11B1 (0.55) | CYP11B1CYP11B2IDO1POLBHTT | |
| SCHEMBL6929093 | 0.83 | CYP11B1 (0.66) | CYP11B1CYP11B2IDO1HTT | |
| SCHEMBL6599480 | 0.83 | CYP11B1 (0.73) | CYP11B1CYP11B2IDO1 | |
| SCHEMBL6748340 | 0.82 | CYP11B1 (0.62) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL27984850 | 0.82 | CYP11B1 (0.62) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| Hydrochloric Acid SCHEMBL2105091 | 0.82 | CYP11B1 (0.62) | CYP11B1CYP11B2IDO1HPGDSP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11668708-B2 | Method for reducing measurement error in latex agglutination immunoassay | SEKISUI MEDICAL CO., LTD. (JP) | 2023-06-06 | — | — | US | claimed |
| US-20030125329-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-07-03 | — | — | US | claimed |
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-07-03 | — | — | US | claimed |
| US-20030119833-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-26 | — | — | US | claimed |
| US-20030114454-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-06-19 | — | — | US | claimed |
| US-20030109528-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-06-12 | — | — | US | claimed |
| US-20030105100-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-05 | — | — | US | claimed |
| US-20030100559-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-05-29 | — | — | US | claimed |
| US-20030096818-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-05-22 | — | — | US | claimed |
| US-20030087905-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-05-08 | — | — | US | claimed |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-05-01 | — | — | US | claimed |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-02-13 | — | — | US | claimed |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| EP-0564356-A1 | 4-phenylaminomethylimidazole derivatives, process for their preparation, angiotensin II receptor antagonists and their application in therapy | FOURNIER INDUSTRIE ET SANTE (FR) | 1993-10-06 | — | — | EP | claimed |
| CN-119816544-A | Composition, cured product, display device, and solid-state imaging device | 住友化学株式会社 | 2025-04-11 | — | — | CN | disclosed |
| US-4207324-A | DIURETICS, HYPOTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1980-06-10 | — | — | US | disclosed |
| EP-0005528-A2 | Imidazole derivatives, their preparation and pharmaceutical compositions | Takeda Chemical Industries, Ltd. (JP) | 1979-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114454-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CYP11B1 1283/4885CYP11B2 2042/4885IDO1 2514/4885 |
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CYP11B1 1283/4885CYP11B2 2042/4885IDO1 2514/4885 |
| US-20030105100-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CYP11B1 1283/4885CYP11B2 2042/4885IDO1 2514/4885 |
| US-20030096818-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CYP11B1 1283/4885CYP11B2 2042/4885IDO1 2514/4885 |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, LCAT, MTTP | CYP11B1 1226/4885CYP11B2 1985/4885IDO1 2992/4885 |
| US-20030109528-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CYP11B1 1283/4885CYP11B2 2042/4885IDO1 2514/4885 |
| US-20030087905-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CYP11B1 1283/4885CYP11B2 2042/4885IDO1 2514/4885 |
| US-20030119833-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CYP11B1 1283/4885CYP11B2 2042/4885IDO1 2514/4885 |
| US-20030100559-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CYP11B1 1283/4885CYP11B2 2042/4885IDO1 2514/4885 |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CYP11B1 1283/4885CYP11B2 2042/4885IDO1 2514/4885 |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, PCTP | CYP11B1 1195/4885CYP11B2 2266/4885IDO1 2018/4885 |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | CYP11B1 1533/4885CYP11B2 2337/4885IDO1 2778/4885 |
| US-20030125329-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | CYP11B1 1283/4885CYP11B2 2042/4885IDO1 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.